Jane Street
ANTX icon

Jane Street’s AN2 Therapeutics ANTX Stock Holding History

Jane Street’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04M Buy
303,649
+285,714
+1,593% +$590K ﹤0.01% 6417
2025
Q4 		$20.4K Buy
+17,935
New +$20.9K ﹤0.01% 10722
2025
Q2 		– Sell
-18,131
Closed -$24.7K – 9545
2025
Q1 		$24.7K Buy
+18,131
New +$22.8K ﹤0.01% 9123
2024
Q2 		– Sell
-59,166
Closed -$192K – 9287
2024
Q1 		$192K Sell
59,166
-279
-0.5% -$3.04K ﹤0.01% 8206
2023
Q4 		$1.22M Buy
+59,445
New +$995K ﹤0.01% 5204

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jane Street's ANTX Position: Q1 2026 in Review

Jane Street increased its AN2 Therapeutics (ANTX) stake by 1,593% in Q1 2026, buying an estimated $590K and bringing the position to 303,649 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #6417.

Jane Street first reported a position in ANTX in Q4 2023 and has held it in 5 quarters since. The position peaked at $1.22M in Q4 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Jane Street held 303,649 shares of AN2 Therapeutics worth $1.04M as of Q1 2026.
  • Jane Street bought 285,714 AN2 Therapeutics shares in Q1 2026, an estimated $590K.
  • AN2 Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6417 holding.
  • Jane Street first reported a position in AN2 Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • Jane Street's AN2 Therapeutics position peaked at $1.22M in Q4 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.